These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22687197)

  • 1. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
    Hottinger AF; Ben Aissa A; Espeli V; Squiban D; Dunkel N; Vargas MI; Hundsberger T; Mach N; Schaller K; Weber DC; Bodmer A; Dietrich PY
    Br J Cancer; 2014 May; 110(11):2655-61. PubMed ID: 24786603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
    Kim R; Prithviraj GK; Shridhar R; Hoffe SE; Jiang K; Zhao X; Chen DT; Almhanna K; Strosberg J; Campos T; Shibata D
    Radiother Oncol; 2016 Feb; 118(2):382-6. PubMed ID: 26861740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
    Grimm SA; Marymont M; Chandler JP; Muro K; Newman SB; Levy RM; Jovanovic B; McCarthy K; Raizer JJ
    J Neurooncol; 2012 Nov; 110(2):237-43. PubMed ID: 22875709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
    Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
    Jeyapalan S; Boxerman J; Donahue J; Goldman M; Kinsella T; Dipetrillo T; Evans D; Elinzano H; Constantinou M; Stopa E; Puthawala Y; Cielo D; Santaniello A; Oyelese A; Mantripragada K; Rosati K; Isdale D; Safran H;
    Am J Clin Oncol; 2014 Oct; 37(5):444-9. PubMed ID: 23388562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
    Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
    Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
    Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
    Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
    Fisher BJ; Hu C; Macdonald DR; Lesser GJ; Coons SW; Brachman DG; Ryu S; Werner-Wasik M; Bahary JP; Liu J; Chakravarti A; Mehta M
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):497-504. PubMed ID: 25680596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.